This is a routine clinical trial recruitment partnership with no financial terms — no immediate trading catalyst. Monitor upcoming HLP003 Phase 3 data readouts and any subsequent financing events for material price movement.
Price Chart
Executive Summary
Helus Pharma (Cybin Inc.) announced a collaboration with TARA Mind to support recruitment for its HLP003 Phase 3 MDD trial and expand veteran mental health outreach, aligning with a recent Executive Order. This is a routine operational partnership with no financial terms disclosed, providing no material change to the company's fundamentals or valuation.
Key Facts
- Collaboration with TARA Mind to support HLP003 Phase 3 recruitment for Major Depressive Disorder
- Partnership aligns with April 18, 2026 Executive Order on mental health treatments
- No financial terms, milestones, or funding amounts disclosed
- HLP003 has FDA Breakthrough Therapy Designation
- Company remains a clinical-stage pharmaceutical company with no approved products
Financial Impact
No financial impact disclosed; partnership is operational in nature with no revenue or cost figures provided.
Risk Factors
- Clinical trial failure or delay for HLP003 Phase 3 program
- No guarantee of regulatory approval or commercialization
- Potential future dilution from capital raises to fund ongoing trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001833141-26-000030 |
| Document: cybininc-form6xk04x28x2026.htm | 0001833141-26-000030 |
| Document: 0001833141-26-000030-index-headers.html | 0001833141-26-000030 |
| Document: 0001833141-26-000030-index.html | 0001833141-26-000030 |
| Document: 0001833141-26-000030.txt | 0001833141-26-000030 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 3 | $10.11 | awaiting T+20 | — | $10.36 (+2.47%) |
Oct 26, 2026 today | 3 | $10.86 | awaiting T+20 | — | $10.36 (−4.56%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 23, 2026 3d ago | 3 | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 21, 2026 5d ago | 6-K | $10.50 | awaiting T+20 | — | $10.36 (−1.33%) |
Oct 15, 2026 11d ago | 6-K | $11.05 | awaiting T+20 | — | $10.36 (−6.24%) |
Oct 15, 2026 11d ago | Press Release | $11.05 | awaiting T+20 | — | $10.36 (−6.24%) |
Oct 8, 2026 18d ago | 6-K | $10.72 | awaiting T+20 | — | $10.36 (−3.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers